Qhslab, INC

QHSLab, Inc. announced robust second quarter and first half 2026 financial results, highlighted by an over 86% increase in Integrated Service Program (ISP) revenue and expanding gross margins.

QHSLab, Inc. announced its participation in the Planet MicroCap Las Vegas 2026 conference, with plans to present its business overview and strategy to investors.

QHSLab, Inc. announced unaudited April 2026 revenue of $325,889, a 57% increase year-over-year, and introduced a new independent representative program called QHS Practice Access Network (PAN).

QHSLab, Inc. announced a 127% year-over-year increase in its Integrated Service Program (ISP) revenue for Q1 2026, reaching $370,000, and launched a new Q-Connect GLP-1 Support Assessment.

QHSLab, Inc. announced robust fiscal year 2025 financial results, showcasing significant revenue growth, expanding margins, and substantial balance sheet improvements driven by its Integrated Service Program.

QHSLab Inc. announced preliminary unaudited 2025 financial results, showcasing over 25% revenue growth, expanded gross margins, and significant convertible debt reduction.

QHSLab, Inc. filed its Q2 2026 10-Q, showing increased revenues driven by its Integrated Service Program, but continued operating losses and a going concern warning.

QHSLab, Inc. reported Q1 2026 results with a 13% increase in revenue driven by its Integrated Service Program, despite a net loss.

QHSLab, Inc. reported a net loss of $99,156 for the nine months ended September 30, 2025, despite a 31.9% revenue increase, as it grapples with significant debt defaults and going concern doubts.

QHSLab, Inc. reported increased revenue for Q2 2025 and the first half of 2025, driven by Integrated Service Program and new clinical study revenue, but faced a significantly higher net loss due to increased operating and default interest expenses, raising substantial doubt about its going concern ability.

QHSLab, Inc. reports increased revenue for the quarter ended March 31, 2025, but continues to experience net losses and going concern uncertainties.

QHSLab, Inc. saw increased revenue and gross profit in the third quarter of 2024, driven by growth in integrated service programs and allergy diagnostic kit sales, but faces ongoing concerns about its ability to continue as a going concern due to significant debt and defaults.

QHSLab delivered 26% revenue growth, positive net income, and eliminated over $1.4M of defaulted convertibles via repurchase, while warning of going-concern risks and material control weaknesses.

QHSLab, Inc.'s annual report reveals revenue growth driven by allergy diagnostic kits and integrated service programs, but also highlights significant debt and uncertainties about the company's ability to continue as a going concern.

QHSLab, Inc. reported a net loss for 2023 and highlighted ongoing concerns about its ability to continue as a going concern.

Marvin Smollar Family Trust files Schedule 13D, reporting beneficial ownership of 2,226,280 shares of QHSLab, Inc. common stock, representing 14.8% of the outstanding shares.

Nicholas Peters has filed an amended Schedule 13G, revealing beneficial ownership of 8.65% of QHSLab, Inc.'s Common Stock.

Nicholas Peters has reported a beneficial ownership of 8.65% of QHSLab, Inc.'s Common Stock, totaling 1,161,049 shares.